125
Views
5
CrossRef citations to date
0
Altmetric
Original Research

Real-world effectiveness of amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide in high-risk patients and other subgroups

, , , , , , & show all
Pages 71-78 | Published online: 21 Jan 2015

Figures & data

Table 1 Summary of patient subgroups

Figure 1 Mean reductions in msSBP and msDBP at 26±8 weeks in subgroups treated with Aml/Val.

Note: Overall group includes 8,603 patients who received Aml/Val, subgroups were defined as elderly (≥65 years of age), obesity (BMI ≥30 kg/m2), and ISH (msSBP ≥140 mmHg and msDBP <90 mmHg).
Abbreviations: Aml/Val, amlodipine/valsartan; BMI, body mass index; BP, blood pressure; CI, confidence interval; ISH, isolated systolic hypertension; LL, lower limit; msDBP, mean sitting diastolic blood pressure; msSBP, mean sitting systolic blood pressure; UL, upper limit.
Figure 1 Mean reductions in msSBP and msDBP at 26±8 weeks in subgroups treated with Aml/Val.

Figure 2 Mean reductions in msSBP and msDBP at 26±8 weeks in subgroups treated with Aml/Val/HCT.

Note: Overall group includes 8,603 patients who received Aml/Val, subgroups were defined as elderly (≥65 years of age), obesity (BMI ≥30 kg/m2), and ISH (msSBP ≥140 mmHg and msDBP <90 mmHg).
Abbreviations: Aml/Val, amlodipine/valsartan; Aml/Val/HCT, amlodipine/valsartan/hydrochlorothiazide; BMI, body mass index; BP, blood pressure; CI, confidence interval; ISH, isolated systolic hypertension; LL, lower limit; msDBP, mean sitting diastolic blood pressure; msSBP, mean sitting systolic blood pressure; UL, upper limit.
Figure 2 Mean reductions in msSBP and msDBP at 26±8 weeks in subgroups treated with Aml/Val/HCT.

Figure 3 Mean reductions in msSBP and msDBP with Aml/Val combination by prior antihypertensive monotherapy class.

Notes: Post hoc analysis. Baseline was defined as prior to start of Aml/Val. The end of the study defined as week 26. Patients who did not take any antihypertensive medication during the observational period, in addition to Aml/Val, and did not switch to Aml/Val/HCT were only included. in addition, patients who did not receive additional treatment prior to study entry were included. Only 14 patients received prior diuretic monotherapy and the mean reduction in BP was −30.7/−19.3 mmHg from baseline (162.9/102.9 mmHg) to endpoint.
Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; Aml/Val, amlodipine/valsartan; Aml/Val/HCT, amlodipine/valsartan/hydrochlorothiazide; ARB, angiotensin receptor blocker; BB, beta-blocker; BP, blood pressure; CCB, calcium channel blocker; CI, confidence interval; LL, lower limit; msBP, mean sitting blood pressure; msDBP, mean sitting diastolic blood pressure; msSBP, mean sitting systolic blood pressure; UL, upper limit.
Figure 3 Mean reductions in msSBP and msDBP with Aml/Val combination by prior antihypertensive monotherapy class.

Figure 4 Mean reductions in msSBP and msDBP with Aml/Val/HCT combination by prior antihypertensive dual therapy classes.

Notes: Post hoc analysis. Baseline was defined as prior to start of Aml/Val/HCT. End of the study defined as week 26. Patients who did not take any antihypertensive medication during the observational period, in addition to Aml/Val/HCT, and did not switch to Aml/Val were only included. in addition, patients who did not receive additional treatment prior to study entry were only included. Only 17 patients received BBs and diuretic combinations and the mean reduction in BP was −35.2/−17.5 mmHg from baseline (161.6/93.7 mmHg).
Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; Aml/Val, amlodipine/valsartan; Aml/Val/HCT, amlodipine/valsartan/hydrochlorothiazide; ARB, angiotensin receptor blocker; BBs, beta-blockers; BP, blood pressure; CCB, calcium channel blocker; CI, confidence interval; Diu, diuretic; LL, lower limit; msBP, mean sitting blood pressure; msDBP, mean sitting diastolic blood pressure; msSBP, mean sitting systolic blood pressure; UL, upper limit.
Figure 4 Mean reductions in msSBP and msDBP with Aml/Val/HCT combination by prior antihypertensive dual therapy classes.